<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505361</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIOPREG</org_study_id>
    <nct_id>NCT01505361</nct_id>
  </id_info>
  <brief_title>Study of a Probiotic Strain to Prevent Mastitis and to Eradicate GBS Colonization</brief_title>
  <acronym>PROBIOPREG</acronym>
  <official_title>Oral Administration of a Probiotic Strain to Pregnant Women: Effects on the Prevention of Lactational Mastitis and on the Eradication of GBS Colonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Complutense de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In previous studies, the investigators have seen that carefully-selected Lactobacillus
      strains are a good alternative to antibiotics for the treatment of lactational mastitis. The
      objective of this new study is to check if they can also have a preventive role when
      administered to women with a history of mastitis with one or more previous infants. Since the
      investigators have also realized that peripartum antibiotherapy (mainly GBS-targeting
      intrapartum prophylaxis)is a predisposing factor for mastitis (because of the selection of
      resistant bacteria), the investigators would also like to test if administration of the
      strains to GBS-colonized pregnant women may lead to GBS eradication. Therefore, a
      mastitis-predisposing factor would de avoid.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinical mastitis confirmed by microbiological cultures and somatic cell counts</measure>
    <time_frame>Weekly during the first 6 months after birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of eradication og GBS colonization as confirmed by microbiological analysis of vaginal exudate and rectal swab</measure>
    <time_frame>At weeks 30, 35, 40 of pregnancy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mastitis</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactobacillus salivarius PS2</intervention_name>
    <description>9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Excipient (milk powder)</intervention_name>
    <description>100 mg/once a day from 30 week of pregnancy until birth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal pregnancy

          -  Healthy women

          -  Lactational mastitis in, at least, a previous lactation period

          -  No symptomatic vaginal infections

        Exclusion Criteria:

          -  Any kind of health problems related to pregnancy

          -  Symptomatic vaginal infections

          -  Allergy to cow's milk protein

          -  Intolerance to lactose

          -  Antibiotic treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan M Rodriguez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complutense University of Madrid, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan M Rodríguez, PhD</last_name>
    <phone>34913943837</phone>
    <email>jmrodrig@vet.ucm.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Public Primary Health Care Centers network</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan M Rodriguez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonides Fernández, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ucm.es/info/probilac/</url>
    <description>website of the research group</description>
  </link>
  <reference>
    <citation>Arroyo R, Martín V, Maldonado A, Jiménez E, Fernández L, Rodríguez JM. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis. 2010 Jun 15;50(12):1551-8. doi: 10.1086/652763.</citation>
    <PMID>20455694</PMID>
  </reference>
  <reference>
    <citation>Jiménez E, Fernández L, Maldonado A, Martín R, Olivares M, Xaus J, Rodríguez JM. Oral administration of Lactobacillus strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. Appl Environ Microbiol. 2008 Aug;74(15):4650-5. doi: 10.1128/AEM.02599-07. Epub 2008 Jun 6.</citation>
    <PMID>18539795</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Complutense de Madrid</investigator_affiliation>
    <investigator_full_name>Juan M. Rodríguez</investigator_full_name>
    <investigator_title>Professor, PhD</investigator_title>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>Lactobacillus salivarius</keyword>
  <keyword>mastitis</keyword>
  <keyword>prevention</keyword>
  <keyword>group B streptococci</keyword>
  <keyword>intrapartum prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastitis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 2, 2015</submitted>
    <returned>July 29, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

